Depression is a complex disorder related to chronic inflammatory processes, chronic stress changes and a hippocampal response. There is a increasing knowledge about the role of glial cells in nutrient supply to neurons, maintenance of synaptic contacts and tissue homeostasis within the CNS. Glial cells, viewed in the past as passive elements with a limited influence on neuronal function, are becoming recognized as active partners of neurons and are starting to be discussed as a possible therapeutic target. Their role in the pathogenesis of depressive disorders is also being reconsidered. Attention is devoted to studies of the different types of antidepressants and their effects on transmembrane signaling, including levels of α subunits of G proteins in C6 glioma cells in vitro as a model of postsynaptic changes in vivo. These models indicate similarities in antidepressant effects on G proteins of brain cells and effector cells of natural immunity, natural killers and granulocytes. Thus, an antidepressant response can exhibit certain common characteristics in functionally different systems which also participate in disease pathogenesis. There are, however, differences in the astrocyte G-protein responses to antidepressant treatment, indicating that antidepressants differ in their effect on glial signalization. Today mainstream approach to neurobiological basis of depressive disorders and other mood illnesses is linked to abnormalities in transmembrane signal transduction via G-protein coupled receptors. Intracellular signalization cascade modulation results in the activation of transcription factors with subsequent increased production of a wide array of products including growth factors and to changes in cellular activity and reactivity., M. Páv, H. Kovářů, A. Fišerová, E. Havrdová, V. Lisá., and Obsahuje bibliografii a bibliografické odkazy
Autoři popisují případ polékového halucinatorního syndromu u 42leté pacientky s karcinomem prsu po infuzi paklitaxelu v rámci adjuvantní chemoterapie dle protokolu AC-T. Kazuistika poukazuje na potencionální riziko paklitaxelu ve smyslu psychotropního nežádoucího účinku a nutnost mezioborové spolupráce, konkrétně pak s psychiatrem. Časná symptomatická psychofarmakologická léčba umožnila bezproblémové dokončení adjuvantní chemoterapie., The authors report on a case of drug-induced hallucinatory syndrome after paclitaxel infusion in a 42-year-old woman with breast carcinoma treated with adjuvant chemotherapy AC-T. This case report highlights the potential risk of paclitaxel causing hallucinatory syndrome. At the same time it indicates the need to cooperate with the psychiatrist. Early symptomatic psychopharmacological treatment enabled the smooth completion of chemotherapy., Ladislav Slováček, Birgita Slováčková, and Literatura 27